Tag: Brain Cancer

Engineered TIMP Molecules Show Potential to Slow Glioblastoma Brain Cancer Spread

March 3, 2025

"Given the lethal nature of GBM and the limited efficacy of current therapies, the application of TIMPs and their engineered minimal variants represents a novel and potentially transformative approach to… read more

Oncotarget

Zika Virus as a Treatment for Brain Cancer: A Systematic Review

October 9, 2024

“Despite limited human evidence, it shows potential benefits.” BUFFALO, NY- October 9, 2024 – A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Zika virus… read more

Oncotarget

Next-Gen Vaccines Offer New Hope Against Glioblastoma

September 9, 2024

“Vaccines have been considered a promising approach for GBM for many years.” BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5,… read more

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.

Oncotarget

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

June 24, 2024

“Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.” BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled,… read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

Oncotarget

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

January 17, 2024

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Oncotarget

GBP3-STING Interaction in Glioblastoma Coordinates Poor Response to Temozolomide

October 17, 2023

“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.” BUFFALO, NY- October 17, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on… read more

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant.

Oncotarget

STAT3 as a Target in H3K27M-mutant DMGs

October 9, 2023

“Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14… read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” BUFFALO, NY- September 13, 2023 – A… read more

Figure 2: Mechanism of radiation resistance in H3K27me3-deficient medulloblastoma.

Oncotarget

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

August 2, 2023

“[...] our discovery of H3K27me3 as an epigenetic marker of radiation resistance in medulloblastoma has a potential to open new therapeutic avenues [...]” BUFFALO, NY- August 2, 2023 – A… read more